Table 3.
Primary and Sensitivity Analyses for Time From Human Immunodeficiency Virus Type 1 (HIV-1) Seroconversion to Various Study End Points Among Subjects With pol Subtype D Infection Versus Those With pol Subtype A Infection
| Study End Point | Hazard Ratio (95% CI) | P |
|---|---|---|
| Primary analysis | ||
| Time to composite end point, unadjusted | 2.4 (1.4–3.7) | .001 |
| Sensitivity analysesa | ||
| Time to composite end point | 2.4 (1.4–3.9) | .001 |
| Time to CD4+ T-cell count <250 cells/mm | 2.6 (1.5–4.8) | .001 |
| Time to death | 3.6 (1.4–9.0) | .008 |
a Adjusted for sex, age, and HIV-1 load set point.